Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010
- PMID: 24800006
- PMCID: PMC4006495
Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010
Abstract
Objective: The most important cause of infant mortality during the first month of life is related to congenital abnormalities. Nevertheless, timely diagnosis of these diseases can reduce the severity of their effects. The present study aimed to investigate the cost-effectiveness of the neonatal screening program in Fars Province, Iran.
Methods: In this study, costs of executing the screening programs, treatment of the diagnosed cases, treatment of affected, non-screened individuals, quality of life, and incremental cost-effectiveness ratios were measured in two study groups.
Findings: Performing the screening programs for phenylketonuria, congenital hypothyroidism, galactosemia, and favism resulted in respectively $3386, $13078, $19641, and $1088 saving per patient. Overall, the study results revealed the cost-effectiveness of execution of the neonatal screening program.
Conclusion: Neonatal screening program is one of the health interventions which lead to long-term beneficial outcome for the patients, financial saving for the society, and improvement of the patients' quantity as well as quality of life.
Keywords: Congenital Hypothyroidism; Cost-utility Analysis; Economic Evaluation; Favism; Galactosemia; Phenylketonuria; Screening.
Figures
Similar articles
-
Lifetime Cost Effectiveness of Phenylketonuria Screening National Program in Iran.Iran J Public Health. 2021 Oct;50(10):2105-2110. doi: 10.18502/ijph.v50i10.7512. Iran J Public Health. 2021. PMID: 35223578 Free PMC article.
-
Neonatal Screening: Cost-utility Analysis for Galactosemia.Iran J Public Health. 2017 Jan;46(1):112-119. Iran J Public Health. 2017. PMID: 28451536 Free PMC article.
-
Appropriateness of Congenital Hypothyroidism Screening Program in Fars Province, Iran: A Retrospective Study from 2005 to 2015.Iran J Med Sci. 2019 May;44(3):245-250. Iran J Med Sci. 2019. PMID: 31182891 Free PMC article.
-
Neonatal screening for inborn errors of metabolism: cost, yield and outcome.Health Technol Assess. 1997;1(7):i-iv, 1-202. Health Technol Assess. 1997. PMID: 9483160 Review.
-
Neonatal biochemical screening for disease.Clin Chim Acta. 2002 Jan;315(1-2):99-110. doi: 10.1016/s0009-8981(01)00716-1. Clin Chim Acta. 2002. PMID: 11728413 Review.
Cited by
-
The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review.Int J Neonatal Screen. 2020 Nov 23;6(4):94. doi: 10.3390/ijns6040094. Int J Neonatal Screen. 2020. PMID: 33238605 Free PMC article.
-
Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics.Metabolites. 2019 Oct 21;9(10):242. doi: 10.3390/metabo9100242. Metabolites. 2019. PMID: 31640247 Free PMC article. Review.
-
Scoping Review of Economic Analyses of Rare Kidney Diseases.Kidney Int Rep. 2024 Sep 12;9(12):3553-3569. doi: 10.1016/j.ekir.2024.09.004. eCollection 2024 Dec. Kidney Int Rep. 2024. PMID: 39698356 Free PMC article.
-
Pilot study of classic galactosemia: Neurodevelopmental impact and other complications urge neonatal screening in Egypt.J Adv Res. 2018 Feb 23;12:39-45. doi: 10.1016/j.jare.2018.02.001. eCollection 2018 Jul. J Adv Res. 2018. PMID: 30038819 Free PMC article.
-
Lifetime Cost Effectiveness of Phenylketonuria Screening National Program in Iran.Iran J Public Health. 2021 Oct;50(10):2105-2110. doi: 10.18502/ijph.v50i10.7512. Iran J Public Health. 2021. PMID: 35223578 Free PMC article.
References
-
- Burgard P, Rupp K, Lindner M, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis. 2012;35(4):613–25. - PubMed
-
- Delavari A, Yar Ahmadi Sh, Birjandi R, et al. Cost-Benefit Analysis of the Neonatal Screening Program Implementation for Congenital Hypothyroidism in I. R. Iran. Int J Endocrinol Metab. 2006;4:84–87.
-
- Downing M, Pollitt R. Newborn bloodspot screening in the UK--past, present and future. Ann Clin Biochem. 2008;45(Pt 1):11–7. - PubMed
-
- World Health Organization (WHO) Control of Genetic Diseases. http://apps.who.int/gb/archive/pdf_files/EB116/B116_3-en.pdf. Assess date: Jul 26, 2013.
LinkOut - more resources
Full Text Sources